Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;12(3):217-226.
doi: 10.1007/s11899-017-0382-1.

A Review of Autologous Stem Cell Transplantation in Lymphoma

Umar Zahid  1   2 , Faisal Akbar  3 , Akshay Amaraneni  4 , Muhammad Husnain  5 , Onyee Chan  5 , Irbaz Bin Riaz  1 , Ali McBride  6 , Ahmad Iftikhar  7 , Faiz Anwer  8   9
Affiliations
Review

A Review of Autologous Stem Cell Transplantation in Lymphoma

Umar Zahid et al. Curr Hematol Malig Rep. 2017 Jun.

Abstract

Purpose of review: Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20-30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients.

Recent findings: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.

Keywords: Autologous stem cell transplantation; High-dose chemotherapy; Lymphoma; Novel agents; Relapsed/refractory; Salvage chemotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Umar Zahid, Faisal Akbar, Akshay Amaraneni, Muhammad Husnain, Onyee Chan, Irbaz Bin Riaz, Ali McBride, and Ahmad Iftikhar each declare no potential conflicts of interest.

Faiz Anwer reports grants from National Cancer Institute and National Institutes of Health.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
    1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42. - PubMed
    1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5. - PubMed
    1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71. - PubMed
    1. Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):2004–9. - PMC - PubMed

Publication types

MeSH terms